Carey RM, Moran AE, Whelton PK. Treatment of Hypertension: A Review. JAMA. 2022;328(18):1849–61. https://doi.org/10.1001/jama.2022.19590.

Article  CAS  PubMed  Google Scholar 

Jones DW, Ferdinand KC, Taler SJ, Johnson HM, Shimbo D, Abdalla M, et al. 2025 AHA/ACC/AANP/AAPA/ABC/ACCP/ACPM/AGS/AMA/ASPC/NMA/PCNA/SGIM Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. JACC. 2025;86(18):1567–678. https://doi.org/10.1016/j.jacc.2025.05.007.

Article  PubMed  Google Scholar 

Colantonio LD, Booth JN 3rd, Bress AP, Whelton PK, Shimbo D, Levitan EB, et al. 2017 ACC/AHA Blood Pressure Treatment Guideline Recommendations and Cardiovascular Risk. J Am Coll Cardiol. 2018;72(11):1187–97. https://doi.org/10.1016/j.jacc.2018.05.074.

Article  PubMed  PubMed Central  Google Scholar 

AAFP Issues New Clinical Practice Guideline on Hypertension. Ann Fam Med. 2023;21(2):190–1. https://doi.org/10.1370/afm.2972.

Article  Google Scholar 

Georgianos PI, Agarwal R. Hypertension in chronic kidney disease-treatment standard 2023. Nephrol Dial Transpl. 2023;38(12):2694–703. https://doi.org/10.1093/ndt/gfad118.

Article  CAS  Google Scholar 

Ku E, Lee BJ, Wei J, Weir MR. Hypertension in CKD: Core Curriculum 2019. Am J Kidney Dis. 2019;74(1):120–31. https://doi.org/10.1053/j.ajkd.2018.12.044.

Article  PubMed  Google Scholar 

Kidney Disease: Improving Global Outcomes Blood Pressure Work G, Cheung AK, Chang TI, Cushman WC, Furth SL, Hou FF, et al. KDIGO 2021 Clinical practice guideline for the management of blood pressure in chronic kidney disease. Kidney Int. 2021;99(3):S1–87. https://doi.org/10.1016/j.kint.2020.11.003.

Article  Google Scholar 

A Randomized Trial of Intensive versus Standard Blood-Pressure Control. N Engl J Med. 2015;373(22):2103–16. https://doi.org/10.1056/NEJMoa1511939.

Article  CAS  Google Scholar 

Bi Y, Li M, Liu Y, Li T, Lu J, Duan P, et al. Intensive Blood-Pressure Control in Patients with Type 2 Diabetes. N Engl J Med. 2025;392(12):1155–67. https://doi.org/10.1056/NEJMoa2412006.

Article  CAS  PubMed  Google Scholar 

Bangalore S, Toklu B, Gianos E, Schwartzbard A, Weintraub H, Ogedegbe G, et al. Optimal Systolic Blood Pressure Target After SPRINT: Insights from a Network Meta-Analysis of Randomized Trials. Am J Med. 2017;130(6):707–e198. https://doi.org/10.1016/j.amjmed.2017.01.004.

Article  PubMed  Google Scholar 

Scheen AJ. Effect of SGLT2 Inhibitors on the Sympathetic Nervous System and Blood Pressure. Curr Cardiol Rep. 2019;21(8):70. https://doi.org/10.1007/s11886-019-1165-1.

Article  PubMed  Google Scholar 

Herat LY, Matthews J, Azzam O, Schlaich MP, Matthews VB. Targeting Features of the Metabolic Syndrome Through Sympatholytic Effects of SGLT2 Inhibition. Curr Hypertens Rep. 2022;24(3):67–74. https://doi.org/10.1007/s11906-022-01170-z.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Pfeifer M, Townsend RR, Davies MJ, Vijapurkar U, Ren J. Effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, on blood pressure and markers of arterial stiffness in patients with type 2 diabetes mellitus: a post hoc analysis. Cardiovasc Diabetol. 2017;16(1):29. https://doi.org/10.1186/s12933-017-0511-0.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Tahara A, Kurosaki E, Yokono M, Yamajuku D, Kihara R, Hayashizaki Y, et al. Effects of SGLT2 selective inhibitor ipragliflozin on hyperglycemia, hyperlipidemia, hepatic steatosis, oxidative stress, inflammation, and obesity in type 2 diabetic mice. Eur J Pharmacol. 2013;715(1):246–55. https://doi.org/10.1016/j.ejphar.2013.05.014.

Article  CAS  PubMed  Google Scholar 

Zala A, Maple-Brown LJ, Shaw JE, Hare MJ. Current evidence and practical guidance for the use of sodium-glucose co-transporter-2 inhibitors in type 2 diabetes. Aust J Gen Pract. 2021;50(4):225–30. https://doi.org/10.31128/ajgp-05-20-5432.

Article  PubMed  Google Scholar 

Beal B, Schutte AE, Neuen BL. Blood Pressure Effects of SGLT2 Inhibitors: Mechanisms and Clinical Evidence in Different Populations. Curr Hypertens Rep. 2023;25(12):429–35. https://doi.org/10.1007/s11906-023-01281-1.

Article  CAS  PubMed  Google Scholar 

Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med. 2015;373(22):2117–28. https://doi.org/10.1056/NEJMoa1504720.

Article  CAS  PubMed  Google Scholar 

Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A, et al. Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2019;380(4):347–57. https://doi.org/10.1056/NEJMoa1812389.

Article  CAS  PubMed  Google Scholar 

Neal B, Perkovic V, Mahaffey KW, Zeeuw Dd, Fulcher G, Erondu N, et al. Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. N Engl J Med. 2017;377(7):644–57. https://doi.org/10.1056/NEJMoa1611925.

Article  CAS  PubMed  Google Scholar 

Bhatt DL, Szarek M, Pitt B, Cannon CP, Leiter LA, McGuire DK, et al. Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease. N Engl J Med. 2021;384(2):129–39. https://doi.org/10.1056/NEJMoa2030186.

Article  CAS  PubMed  Google Scholar 

Avgerinos I, Karagiannis T, Kakotrichi P, Michailidis T, Liakos A, Matthews DR, et al. Sotagliflozin for patients with type 2 diabetes: A systematic review and meta-analysis. Diabetes Obes Metab. 2022;24(1):106–14. https://doi.org/10.1111/dom.14555.

Article  CAS  PubMed  Google Scholar 

Wu J, Zhao X, Chen H, Zhu S. Metabolic effects of the dual SGLT 1/2 inhibitor sotagliflozin on blood pressure and body weight reduction in people with diabetes: An updated meta-analysis of randomized controlled trials. J Diabetes Complications. 2022;36(12):108352. https://doi.org/10.1016/j.jdiacomp.2022.108352.

Article  CAS  PubMed  Google Scholar 

Group E-KC. Empagliflozin in Patients with Chronic Kidney Disease. N Engl J Med. 2023;388(2):117–27. https://doi.org/10.1056/NEJMoa2204233.

Article  Google Scholar 

Heerspink HJL, Stefánsson BV, Correa-Rotter R, Chertow GM, Greene T, Hou F-F, et al. Dapagliflozin in Patients with Chronic Kidney Disease. N Engl J Med. 2020;383(15):1436–46. https://doi.org/10.1056/NEJMoa2024816.

Article  CAS  PubMed  Google Scholar 

Perkovic V, Jardine MJ, Neal B, Bompoint S, Heerspink HJL, Charytan DM, et al. Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy. N Engl J Med. 2019;380(24):2295–306. https://doi.org/10.1056/NEJMoa1811744.

Article  CAS  PubMed  Google Scholar 

Williams JS, Williams GH. 50th Anniversary of Aldosterone. J Clin Endocrinol Metabolism. 2003;88(6):2364–72. https://doi.org/10.1210/jc.2003-030490.

Article  CAS  Google Scholar 

Kaur J, Rout P, Physiology. Renin Angiotensin System. StatPearls. Treasure Island (FL): StatPearls Publishing; 2026.

Google Scholar 

Booth RE, Johnson JP, Stockand JD. ALDOSTERONE. Adv Physiol Educ. 2002;26(1):8–20. https://doi.org/10.1152/advan.00051.2001.

Article  PubMed  Google Scholar 

Nguyen Dinh Cat A, Jaisser F. Extrarenal effects of aldosterone. Curr Opin Nephrol Hypertens. 2012;21(2):147–56. https://doi.org/10.1097/MNH.0b013e32834fb25b.

Article  CAS  PubMed  Google Scholar 

Schmieder RE, Hilgers KF, Schlaich MP, Schmidt BM. Renin-angiotensin system and cardiovascular risk. Lancet. 2007;369(9568):1208–19. https://doi.org/10.1016/s0140-6736(07)60242-6.

Article  CAS  PubMed  Google Scholar 

Remuzzi